Benzodiazepine-Associated Carcinogenesis: Focus on Lorazepam-Associated Cancer Biomarker Changes in Overweight Individuals
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective Cellular, animal, and human epidemiological studies suggested that benzodiazepines increase the risk of cancer and cancer mortality. Obesity is also clearly linked to carcinogenesis. However, no human studies have examined benzodiazepine-associated carcinogenesis as assessed by changes in cancer biomarkers. Methods A total of 19 patients were recruited, and received a 6-week treatment of 0.5 mg lorazepam. The measured cancer biomarkers were angiopoietin-2 (ANG-2), soluble CD40 ligand, epidermal growth factor, endoglin, soluble Fas ligand (sFASL), heparin-binding EGF-like growth factor (HB-EGF), insulin-like growth factor binding protein, interleukin (IL)-6, IL-8, IL-18, plasminogen activator inhibitor (PLGF), placental growth factor, transforming growth factor (TGF)-α, tumor necrosis factor (TNF)-α, urokinase-type plasminogen (uPA), vascular endothelial growth factor (VEGF)-A, VEGF-C, and VEGF-D. Results Six cancer biomarkers were significantly increased in all patients as a whole. The subgroup analysis revealed a distinct pattern of change. Overweight patients showed a significant increase in 11 cancer biomarkers, including ANG-2, sFASL, HB-EGF, IL-8, PLGF, TGF-α, TNF-α, uPA, VEGF-A, VEGF-C, and VEGF-D. However, normal-weight patients did not show any changes in cancer biomarkers. Conclusion Adiposity may have primed the carcinogenic potential, leading to lorazepam-associated carcinogenesis in overweight patients. Epidemiological studies addressing this issue should consider the potential modulator contributing to benzodiazepine-associated carcinogenesis.
Abstract
Objective Cellular, animal, and human epidemiological studies suggested that benzodiazepines increase the risk of cancer and cancer mortality. Obesity is also clearly linked to carcinogenesis. However, no human studies have examined benzodiazepine-associated carcinogenesis as assessed by changes in cancer biomarkers. Methods A total of 19 patients were recruited, and received a 6-week treatment of 0.5 mg lorazepam. The measured cancer biomarkers were angiopoietin-2 (ANG-2), soluble CD40 ligand, epidermal growth factor, endoglin, soluble Fas ligand (sFASL), heparin-binding EGF-like growth factor (HB-EGF), insulin-like growth factor binding protein, interleukin (IL)-6, IL-8, IL-18, plasminogen activator inhibitor (PLGF), placental growth factor, transforming growth factor (TGF)-α, tumor necrosis factor (TNF)-α, urokinase-type plasminogen (uPA), vascular endothelial growth factor (VEGF)-A, VEGF-C, and VEGF-D. Results Six cancer biomarkers were significantly increased in all patients as a whole. The subgroup analysis revealed a distinct pattern of change. Overweight patients showed a significant increase in 11 cancer biomarkers, including ANG-2, sFASL, HB-EGF, IL-8, PLGF, TGF-α, TNF-α, uPA, VEGF-A, VEGF-C, and VEGF-D. However, normal-weight patients did not show any changes in cancer biomarkers. Conclusion Adiposity may have primed the carcinogenic potential, leading to lorazepam-associated carcinogenesis in overweight patients. Epidemiological studies addressing this issue should consider the potential modulator contributing to benzodiazepine-associated carcinogenesis.
참고문헌 (19)
- Rudolph U, "Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes", Nat Rev Drug Discov, 10, pp.685~697 (2011)
- Kripke DF, "Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit", F1000Res, 5, pp.918~ (2016)
- Miyawaki I, "Mechanism of clobazam-induced thyroidal oncogenesis in male rats", Toxicol Lett, 145, pp.291~301 (2003)
- Iida M, "Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-14,643", Carcinogenesis, 24, pp.757~770 (2003)
- Kripke DF, "Hypnotics' association with mortality or cancer: a matched cohort study", BMJ Open, 2, pp.e000850~ (2012)
- Iqbal U, "Is long-term use of benzodiazepine a risk for cancer", Medicine (Baltimore), 94, pp.e483~ (2015)
- Kunert-Radek J, "Inhibition of rat pituitary tumor cell proliferation by benzodiazepines in vitro", Neuroendocrinology, 59, pp.92~96 (1994)
- Kim DH, "Comparative anticancer effects of flavonoids and diazepam in cultured cancer cells", Biol Pharm Bull, 31, pp.255~259 (2008)
- Pottegard A, "Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study", Br J Clin Pharmacol, 75, pp.1356~1364 (2013)
- Hanahan D, "The hallmarks of cancer", Cell, 100, pp.57~70 (2000)
- Renehan AG, "Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies", Lancet, 371, pp.569~578 (2008)
- Calle EE, "Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults", N Engl J Med, 348, pp.1625~1638 (2003)
- Guh DP, "The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis", BMC Public Health, 9, pp.88~ (2009)
- Richens JL, "Quantitative validation and comparison of multiplex cytokine kits", J Biomol Screen, 15, pp.562~568 (2010)
- Khandekar MJ, "Molecular mechanisms of cancer development in obesity", Nat Rev Cancer, 11, pp.886~895 (2011)
- Renehan AG, "Adiposity and cancer risk: new mechanistic insights from epidemiology", Nat Rev Cancer, 15, pp.484~498 (2015)
- Brambilla G, "Genotoxicity and carcinogenicity studies of benzodiazepines", Pharmacol Res, 56, pp.443~458 (2007)
- Iakovidou-Kritsi Z, "In vitro genotoxicity of two widely used benzodiazepines: alprazolam and lorazepam", Arist Uni Med J, 36, pp.39~44 (2009)
- Kripke DF, "Possibility that certain hypnotics might cause cancer in skin", J Sleep Res, 17, pp.245~250 (2008)